Potential role for the common cystic fibrosis δF508 mutation in Crohn's disease

Inflammatory Bowel Diseases

Volumn 13, Issue 5, 2007, Pages 531-536

  Bresso, Francesca ^a   Askling, Johan ^b   Astegiano, Marco ^d   Demarchi, Brunello ^d   Sapone, Nicoletta ^d   Rizzetto, Mario ^d   Gionchetti, Paolo ^e   Lammers, Karen M ^e   De Leone, Annalisa ^f   Riegler, Gabriele ^f   Nimmo, Elaine R ^g   Drummond, Hazel ^g   Noble, Colin ^g   Torkvist, Leif ^b   Ekbom, Anders ^b,h   Zucchelli, Marco ^a   Lofberg, Robert ^b,c   Satsangi, Jack ^g   Pettersson, Sven ^a,i   D'Amato, Mauro ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Sophiahemmet Hospital   (Sweden)

^d MOLINETTE HOSPITAL   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

CFTR; Genetics; Inflammatory bowel disease

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; CYSTIC FIBROSIS; DEMOGRAPHY; ENTERITIS; FEMALE; GENE LOCUS; GENE MUTATION; GENOTYPE; HETERODUPLEX ANALYSIS; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CROHN DISEASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; ITALY; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; SCOTLAND; SWEDEN;

EID: 34249028548     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20067     Document Type: Article

References (37)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
2. Van Heel DA, McGovern DP, Jewell DP. Crohn's disease: genetic susceptibility, bacteria, and innate immunity. Lancet. 2001;357:1902-1904.
3. Fedorak RN, Madson NL. Naturally occurring and experimental models of inflammatory bowel disease, 5th ed. Philadelphia: Saunders; 2000: 113-143
4. Schreiber S, Rosenstiel P, Albrecht M, et al. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet. 2005;6:376-388.
5. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
6. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
7. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001;357:1925-1928.
8. McGovern DP, Hysi P, Ahmad T, et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet. 2005;14:1245-1250.
9. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004;36: 476-480.
10. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 2004;36:471-475.
11. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003;124:26-33.
12. Ho GT, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005;128:288-296.
13. Brant SR, Panhuysen CI, Nicolae D, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003; 73:1282-1292.
14. Gasche C, Grundtner P. Genotypes and phenotypes in Crohn's disease: do they help in clinical management? Gut. 2005;54:162-167.
15. Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003;124:1767-1773.
16. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002; 122:854-866.
17. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122:867-874.
18. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002;359:1661-1665.
19. Helio T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut. 2003;52:558-562.
20. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet. 1996;14:199-202.
21. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet. 1995;29:777-807.
22. Greger R. Role of CFTR in the colon. Annu Rev Physiol. 2000;62:467-491.
23. Grubb BR, Gabriel SE. Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis. Am J Physiol. 1997;273:G258-266.
24. Schroeder TH, Lee MM, Yacono PW, et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci USA. 2002;99:6907-6912.
25. Pier GB, Grout M, Zaidi T, et al. Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature. 1998;393:79-82.
26. Gabriel SE, Brigman KN, Koller BH, et al. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science. 1994;266:107-109.
27. Dodge JA, Burton L. Letter: heterozygote advantage in cystic fibrosis. Lancet. 1975;1:572-573.
28. Gasparini P, Arbustini E, Restagno G, et al. Analysis of 31 CFTR mutations by polymerase chain reaction/oligonucleotide ligation assay in a pilot screening of 4476 newborns for cystic fibrosis. J Med Screen. 1999;6:67-69.
29. Dahl N, Grandell U, Martinsson T, et al. Frequency of four cystic fibrosis mutations in a Swedish population. Acta Paediatr. 1993;82: 609.-
30. Boyle MP. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med. 2003;9:498-503.
31. Schroeder SA, Gaughan DM, Swift M. Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis. Nat Med. 1995;1:703-705.
32. Dahl M, Tybjaerg-Hansen A, Lange P, et al. DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet. 1998;351:1911-1913.
33. Arnott ID, Nimmo ER, Drummond HE, et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immunol. 2004;5:417-425.
34. Hogenauer C, Santa Ana CA, Porter JL, et al. Active intestinal chloride secretion in human carriers of cystic fibrosis mutations: an evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion. Am J Hum Genet. 2000;67:1422-1427.
35. Lyczak JB. Commensal bacteria increase invasion of intestinal epithelium by Salmonella enterica serovar Typhi. Infect Immunol. 2003;71: 6610-6614.
36. Lukacs GL, Mohamed A, Kartner N, et al. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J. 1994;13:6076-6086.
37. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology. 2005;128:891-906.